A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1735-1744

  Simoens, Steven ^a   Decramer, Marc ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acute bacterial sinusitis; Chronic bronchitis; Community acquired pneumonia; Economic evaluation; Moxifloxacin; Respiratory tract infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CEFUROXIME AXETIL; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN;

ACUTE DISEASE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; COMMUNITY-ACQUIRED INFECTIONS; COSTS AND COST ANALYSIS; HUMANS; PNEUMONIA, BACTERIAL; QUINOLINES; RESPIRATORY TRACT INFECTIONS; SINUSITIS;

EID: 48049111154     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1735     Document Type: Review

References (43)

1. World Health Organisation: The World Health Report 2004 - changing history. Geneva: World Health Organisation; 2004
2. Martin SJ, Sahloff EG, Close SJ. Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections. Expert Opin Pharmacother 2002;3:1251-66
3. Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999;43:1-11
4. Miravittles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-93
5. Aliyu ZY, Aliyu MH, Mccormick K. Determinants for hospitalization in 'low-risk' community acquired pneumonia. BMC Infect Dis 2003;3:11
6. Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177-85
7. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-28
8. Niederman MS. Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin Infect Dis 2005;41(Suppl 2):158-66
9. American Thoracic Society and European Respiratory Society: standards for the diagnosis and management of patients with COPD. New York, NY; American Thoracic Society and European Respiratory Society, 2004. Available from: http://www.thoracic.org/sections/copd/resources/ copddoc.pdf [Last accessed 28 February 2008]
10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
11. Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64
12. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005;59:230-8
13. Lau J, Zucker D, Engels EA, et al. Diagnosis and treatment of acute bacterial rhinosinusitis. Rockville MD: Agency for Health Care Policy and Research, 1999
14. Klossek JM, Siegert R, Nikolaidis P, et al. Comparison of the efficacy and safety of moxilloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003;117:43-51
15. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 8039) and cefuroxime axedl in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337-44
16. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods fiar the economic evaluation of health care programmes. Oxford University Press: Oxford; 2005
17. Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977-89
18. Martin M, Moore L, Quilici S, et al. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin 2008;24:737-51
19. Sabes-Figuera R, Segu JL, Paig-Junoy J, Torres A. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2008;9:23-32
20. Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003;9:590-9
21. Valcke Y. CAP guidelines: why differences between Belgian and American/ Canadian guidelines? Louvain: Universitd Catholique de Louvain, 2001. Available from: http://www.farm.ucl.ac.be/scminfec/ Atelier-Mandell-23-11-01[Valcke/Valcke.pdf [Last accessed 25 February 2008]
22. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
23. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526-35
24. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238-46
25. Lloyd A, Battleman D, Choudhri S, et al. Cost-effectiveness analysis of intravenous moxifloxacin compared to levofloxacin in hospitalized elderly patients with community-acquired pneumonia. Abstract presented at the Sixth European Congress of Clinical Microbiology and Infectious Diseases; 2006 April 1-4; Nice, France
26. Davis SL, Delgado G, Mckinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41(Suppl 2):136-43
27. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996;42:410-25
28. Llor C, Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract 2004;58:937-44
29. Miravittles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 2001;17:928-33
30. Miravitlles M, Llor C, Naberan K, et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 2005;99:955-65
31. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002;49:897-903
32. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous ndmeni tration in man. J Antimicrob Chemother 1999;43(Suppl B):83-90
33. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-50
34. Keating KN, Friedman HS, Perfetto EM. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges. Curr Med Res Opin 2006;22:327-33
35. Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520
36. Spiritus E. Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure. Am J Manag Care 2000;23(Suppl 1):1216-21
37. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause far concern. Am J Med 2004;117(Suppl 3A):39-50
38. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002;50(Suppl S2):87-92
39. Welte T, Marre R, Suttrop N. What is new in the treatment of community-acquired pneumonia? Med Klin (Munich) 2006;101:313-20
40. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
41. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pultnonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76
42. Pallares R, Fenoll A, Linares J; The Spanish Pneumococcal Infection Study Network. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003;22(Suppl 1):15-24
43. Simoens S, Verhaegen J, Laekeman G, Peetermans WE. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62-8